PainReform Initiates OcuRing-K Development Plan Targeting 4.5 Million Cataract Surgeries Annually
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: Newsfilter
- Development Plan Launch: PainReform has officially initiated the development plan for OcuRing-K following its majority investment in LayerBio, aiming to provide sustained-release ocular therapy for approximately 4.5 million cataract surgeries performed annually, significantly enhancing postoperative recovery experiences for patients.
- Clinical Trial Progress: The development of OcuRing-K has advanced to Phase II clinical trials, expected to reduce postoperative pain and inflammation while decreasing patient reliance on traditional eye drops, thereby improving patient compliance and treatment outcomes.
- Significant Market Potential: With a global cataract surgery market exceeding $9 billion annually, OcuRing-K's innovative design aims to simplify postoperative management and reduce medication burdens for patients, positioning it to capture a significant share in a high-demand market.
- Clear Technological Advantage: OcuRing-K's sustained-release mechanism provides stable drug concentrations while minimizing systemic side effects, particularly beneficial for elderly patients, marking PainReform's strategic positioning and technological innovation in the ophthalmic treatment sector.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PRFX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PRFX
About PRFX
PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
Continue Reading
PainReform Ltd. Changes Name to PRF Technologies, Stock Rises 48%
- Significant Stock Surge: PainReform Ltd., now PRF Technologies, saw its stock rise by 48% to $1.22 on Friday, indicating strong market performance and reflecting investor optimism regarding the company's new strategic direction.
- Surge in Trading Volume: The stock traded 35.49 million shares, significantly exceeding the average volume of 672,850 shares, suggesting heightened market interest in the company's transformation and potentially attracting more investor participation.
- Expanded Product Portfolio: The name change aims to better represent the company's broadened portfolio, which includes non-opioid postoperative pain therapy PRF-110 and OcuRing-K for cataract surgery, demonstrating a diversification strategy intended to reduce reliance on any single product outcome.
- Strong Technical Indicators: PRFX is currently trading 21.12% above its 20-day simple moving average, indicating short-term strength; despite a 60.93% decline over the past year, the current technical signals suggest potential rebound opportunities.
Continue Reading